<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258609</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52120-007</org_study_id>
    <nct_id>NCT00258609</nct_id>
  </id_info>
  <brief_title>Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study</brief_title>
  <official_title>A 12-Week Prospective, Double-Blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 120 Unit, and 240 unit of botulinum toxin A
      are effective in the treatment of migraine without aura prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week, prospective double-blinded, randomized, multicenter study of placebo, 120
      Unit, and 240 unit of botulinum toxin A ( Dysport ® ) injection for patient with a diagnosis
      of Migraine without aura according to International Headache Society criteria. It is designed
      to evaluate the efficacy, safety, tolerability and optimum dose of Botulinum toxin type A
      (Dysport ®)injection for migraine without aura prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date>June 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline of Area undercurve of headache diary ( total headache score).</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline of total duration of migraine attack( hours) in 4 weeks.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline of migraine frequency</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>MIDAS score, SF36</measure>
  </secondary_outcome>
  <enrollment>128</enrollment>
  <condition>Migraine Without Aura Prophylaxis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • The patient must give written (personally signed and dated) informed consent before
        completing any study-related procedure, which means any assessment or evaluation that would
        not have formed part of the normal medical care of the patient.• Able to give written
        inform consent and have a copied one.• Male or female patient age 18 – 65.• Patients are
        fulfil the International Headache Society diagnostic criteria for migraine• Patients
        experience an average of 2 to 8 migraine attacks per month over the 3 months and if they
        recorded 2 to 8 migraine attacks during the screening period. • Patients with prophylactic
        treatment for migraine have been unchanged for 3 months. • Able to continuation anti –
        migraine drugs.• Female patient in good general health who is potentially fertile and
        sexually active must be instructed by the investigator to avoid pregnancy during the study
        by condom or other contraceptive measure and has negative urine pregnancy test. (if
        possible at each visit a control of the urine pregnancy test will be performed).• Patients
        have to judge reliable for medication compliance and recording the effects of medication,
        as well as clearly motivated to obtain benefit from treatment. • The normal physical and
        neurological examinations during the whole study period. • Normal result for haematology
        test • Liver transaminase inferior than 2 upper normal values of the laboratory.

        Exclusion Criteria:

        • Patients are fulfil the international Headache Society criteria diagnostic for pure
        migraine with aura.• The patient is pregnant or lactating.• The patient is a female at risk
        of pregnancy during the study, not taking adequate precautions against pregnancy.• The
        patient has a known hypersensitivity to any of the test materials or related compounds.•
        The patient is unable or unwilling to comply fully with the protocol.• The patient has
        received any unlicensed drug within the previous 6 months.• Treatment with investigational
        drug (s) within 6 months before the screening visit.• The patient has previously entered
        this study.• Patient with past history of predominant tension type headache, botulism,
        other neuromuscular disorder (e.g. myasthenia gravis, Lambert – Elton Syndrome)• Patient
        with significant medical / neurological / psychiatric disorders such as blood
        dyscrasia,thrombocytopenia, rheumatoid arthritis, congestive heart failure, coronary artery
        heart diseases, dementia, psychosis, major depression or other conditions which could
        influence the clinical trial. • History of drugs abuse (narcotic (s), cafergot, or others)
        or drug (botulinum toxin type A) allergy.• Treatment with BTX A within 6 month Treatment or
        any medical condition that may have put the participant at risk with exposure to BTX-A
        (neuromuscular disorders, aminoglycoside antibiotics, curare-like agents).• History of
        migrainous infarction, hemiplegic migraine.• Unable to fill patient diary at home during
        migraine attack.• Patient who plan to schedule elective surgery during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siwaporn Chankrachang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Neurological Center, Faculty of Medicine,Chiang Mai University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Neurology, Department of Medicine, Bhumipol Hospital.</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Neurology, Department of Medicine, Pramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Neurology, Prasart Neurological Institute, Public Health Ministry.</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Neurological Center, Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Sappasithiprasong Hospital, Public Health Ministry</name>
      <address>
        <city>Ubonratchatani</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000 Jun;40(6):445-50.</citation>
    <PMID>10849039</PMID>
  </reference>
  <reference>
    <citation>Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004 Oct;24(10):838-43.</citation>
    <PMID>15377314</PMID>
  </reference>
  <reference>
    <citation>Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004 Sep;44(8):794-800.</citation>
    <PMID>15330826</PMID>
  </reference>
  <reference>
    <citation>Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002 Nov;27(11):552-8. Review.</citation>
    <PMID>12417130</PMID>
  </reference>
  <reference>
    <citation>Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-68. Review.</citation>
    <PMID>9826987</PMID>
  </reference>
  <reference>
    <citation>Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33.</citation>
    <PMID>14715398</PMID>
  </reference>
  <reference>
    <citation>Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001 Aug;10(8):1531-44. Review.</citation>
    <PMID>11772268</PMID>
  </reference>
  <reference>
    <citation>Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S125-32. Review.</citation>
    <PMID>12569959</PMID>
  </reference>
  <reference>
    <citation>Krämer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol. 2003 Feb;250(2):188-93.</citation>
    <PMID>12574949</PMID>
  </reference>
  <reference>
    <citation>Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci. 2002 Dec 15;205(1):59-63.</citation>
    <PMID>12409185</PMID>
  </reference>
  <reference>
    <citation>Caputi CA. Effectiveness of BoNT-A in the treatment of migraine and its ability to repress CGRP release. Headache. 2004 Sep;44(8):837-8.</citation>
    <PMID>15330838</PMID>
  </reference>
  <reference>
    <citation>Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. 2004 Sep;44(8):801-5.</citation>
    <PMID>15330827</PMID>
  </reference>
  <reference>
    <citation>Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004 Jan;44(1):35-42; discussion 42-3.</citation>
    <PMID>14979881</PMID>
  </reference>
  <reference>
    <citation>Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. Review.</citation>
    <PMID>11825307</PMID>
  </reference>
  <reference>
    <citation>Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003 Jul-Aug;43 Suppl 1:S9-15. Review.</citation>
    <PMID>12887389</PMID>
  </reference>
  <reference>
    <citation>Blumenfeld AM, Dodick DW, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin. 2004 Apr;22(2):167-75. Review.</citation>
    <PMID>15222577</PMID>
  </reference>
  <reference>
    <citation>Göbel H. Botulinum toxin in migraine prophylaxis. J Neurol. 2004 Feb;251 Suppl 1:I8-11. Review.</citation>
    <PMID>14991336</PMID>
  </reference>
  <reference>
    <citation>Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. Cephalalgia. 2002 Nov;22(9):699-710. Review.</citation>
    <PMID>12421155</PMID>
  </reference>
  <verification_date>December 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2005</study_first_submitted>
  <study_first_submitted_qc>November 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>December 22, 2005</last_update_submitted>
  <last_update_submitted_qc>December 22, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2005</last_update_posted>
  <keyword>Botulinum toxin type A,</keyword>
  <keyword>Dysport®,Dysport</keyword>
  <keyword>Migraine without aura,</keyword>
  <keyword>Migraine prophylaxis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

